1. Identification of BMI1 Promoter Inhibitors from Beaumontia murtonii and Eugenia operculata.
- Author
-
Kaneta Y, Arai MA, Ishikawa N, Toume K, Koyano T, Kowithayakorn T, Chiba T, Iwama A, and Ishibashi M
- Subjects
- Animals, Antineoplastic Agents chemistry, Antineoplastic Agents isolation & purification, Antineoplastic Agents pharmacology, Blotting, Western, Carcinoma, Hepatocellular drug therapy, Cardenolides chemistry, Cardenolides isolation & purification, Cardenolides pharmacology, Cell Line, Tumor, HCT116 Cells, HEK293 Cells, Humans, Inhibitory Concentration 50, Liver Neoplasms drug therapy, Mice, Molecular Structure, Neoplastic Stem Cells drug effects, Plant Leaves chemistry, Thailand, Triterpenes chemistry, Triterpenes isolation & purification, Triterpenes pharmacology, Apocynaceae chemistry, Eugenia chemistry, Polycomb Repressive Complex 1 metabolism
- Abstract
B-Cell-specific Moloney murine leukemia virus insertion region 1 (BMI1) is a core component of the polycomb repressive complex 1 (PRC1). Abnormal expression of BMI1 is associated with a number of human malignances and cancer stem cells (CSCs), which cause chemotherapy resistance. Therefore, small molecules that inhibit BMI1 expression are potential candidates for cancer therapy. In this study, a cell-based reporter gene assay was developed that allowed BMI1 promoter activity to be measured in 293T human embryonic kidney cells based on luciferase expression levels. Using this screening assay, the methanol-soluble extracts of Beaumontia murtonii and Eugenia operculata were selected as leads. Bioassay-guided fractionation of the extracts led to the isolation of three known cardenolides (1-3) and one new compound (4) from B. murtonii and two known triterpenoids (5 and 6) and one new compound (7) from E. operculata. These seven compounds inhibited BMI1 promoter activity (IC
50 range 0.093-23.0 μM), and the most active compound, wallichoside (1), was further evaluated. Western blot analysis revealed that wallichoside (1) decreases BMI1 protein levels in HCT116 human colon carcinoma cells, and flow cytometry analysis showed that it significantly reduced levels of the CSC biomarker epithelial cell adhesion molecule. Wallichoside (1) also inhibited sphere formation of Huh7 human hepatocellular carcinoma cells, indicating that it diminished the self-renewal capability of CSCs.- Published
- 2017
- Full Text
- View/download PDF